Premium
Effects of temazepam on saccadic eye movements: Concentration‐effect relationships in individual volunteers
Author(s) -
Steveninck Alfred L,
Verver Susanne,
Schoemaker Hendrik C,
Pieters Monique S M,
Kroon Ria,
Breimer Douwe D,
Cohen Adam F
Publication year - 1992
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1992.162
Subject(s) - temazepam , saccadic masking , crossover study , placebo , anesthesia , confidence interval , medicine , pharmacodynamics , ophthalmology , pharmacokinetics , eye movement , receptor , alternative medicine , pathology , benzodiazepine
Saccadic eye movements were analyzed after single oral doses of 20 mg temazepam and placebo in a randomized, double‐blind crossover study in eight healthy volunteers. For an optimal evaluation of concentration‐effect relationships, 18 blood samples and 43 effect measures were obtained over 33½ hours. After placebo, saccadic peak velocity decreased within the first hour, with average values remaining 6.2% to 12.1% below baseline up to 15 hours after intake. After temazepam, significant changes in peak velocity occurred for 5 hours, with maximum decreases averaging 29.2% (95% confidence interval, 10.0 to 37.2). The apparent duration of effects ranged from 3 to 9 hours in individual subjects. Linear concentration‐effect relationships were demonstrated for peak velocity, with individual slopes ranging from −0.11 to −0.46 deg/sec · (ng/ml) −1 (average r = −0.82, all p < 0.01). Differences in protein binding of temazepam did not account for the approximate fourfold variability in individual sensitivities to temazepam. By increasing the frequency of measurements, the accuracy of pharmacodynamic evaluations was clearly enhanced in this study. Clinical Pharmacology and Therapeutics (1992) 52, 402–408; doi: 10.1038/clpt.1992.162